This is a working overview of hGH fragment, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-03-05. Anything still debated is marked as such rather than presented as settled.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
== Post summit == From 11 to 12 November 2025, the G7 Foreign Ministers' Meeting was held at Niagara-on-the-Lake, and joint statement was issued. The joint statement showed their consensus on Ukraine and Sudan, but stayed away from contentious issues like the US military strikes on boats in the Caribbean and trade. They are increasing the economic costs to Russia and exploring measures against those who finance Russia's war efforts. Also, they raised alarm over China's military buildup and reiterated their resolve to create an alternative to its dominance in critical mineral supplies, and reaffirmed the importance of a Free and Open Indo-Pacific based on the rule of law.
== Genome == The genome of T. pallidum was first sequenced in 1998 and revealed a small 1.14 Mbp genome, one of the smallest bacterial genomes. The GC-content is 52.8%. The DNA sequences of T. pallidum species are more than 99.7% identical, and PCR-based assays are effective at differentiating these species. About 92.9% of DNA was determined to be open reading frames, 55% of which had predicted biological functions, while 17% matched hypothetical proteins of unknown function in other organisms and the remainder (28%) did not have significant similarity to other known sequences. The small size of the T. pallidum genome indicates that the species has limited metabolic capabilities, and thus mostly relies on its host for many molecules typically provided by biosynthetic pathways. For instance, it is missing genes encoding key enzymes in oxidative phosphorylation and the tricarboxylic acid cycle. Thus, T. pallidum is no longer able to synthesize fatty acids, nucleic acids, and amino acids, instead relying on its mammalian hosts for these materials. T.pallidum's low levels of diversity within its DNA sequence, forces the pathogen to utilize horizontal gene transfer for genetic diversity, although the specific mechanism is not well understood. It may possibly be a clonal species that still employs recombination. The strains T. pallidum pertenue (TPE) and T.pallidum endemicum (TEN) also experience gene transfer via different subspecies but are notably geographically isolated.
=== Hydrolysis === Amides hydrolyse in hot alkali as well as in strong acidic conditions. Acidic conditions yield the carboxylic acid and the ammonium ion while basic hydrolysis yield the carboxylate ion and ammonia. The protonation of the initially generated amine under acidic conditions and the deprotonation of the initially generated carboxylic acid under basic conditions render these processes non-catalytic and irreversible. Electrophiles other than protons react with the carbonyl oxygen. This step often precedes hydrolysis, which is catalyzed by both Brønsted acids and Lewis acids. Peptidase enzymes and some synthetic catalysts often operate by attachment of electrophiles to the carbonyl oxygen.
== Disadvantages == The Bradford assay is linear over a short range, typically from 0 μg/mL to 2000 μg/mL, often making dilutions of a sample necessary before analysis. In making these dilutions, error in one dilution is compounded in further dilutions resulting in a linear relationship that may not always be accurate. Basic conditions and detergents, such as SDS, can interfere with the dye's ability to bind to the protein through its side chains. The reagents in this method tend to stain the test tubes. Same test tubes cannot be used since the stain would affect the absorbance reading. This method is also time sensitive. When more than one solution is tested, it is important to make sure every sample is incubated for the same amount of time for accurate comparison. A limiting factor in using Coomassie-based protein determination dyes stems from the significant variation in color yield observed across different proteins This limiting factor is notably evident in collagen-rich protein samples, like pancreatic extracts, where both the Lowry and Bradford methods tend to underestimate protein content. It is also inhibited by the presence of detergents, although this problem can be alleviated by the addition of cyclodextrins to the assay mixture. Much of the non-linearity stems from the equilibrium between two different forms of the dye which is perturbed by adding the protein. The Bradford assay linearizes by measuring the ratio of the absorbances, 595 over 450 nm. This modified Bradford assay is approximately 10 times more sensitive than the conventional one.
Thin basement membrane disease is an autosomal dominant inherited disease characterized by thin glomerular basement membranes on electron microscopy. It is a benign condition that causes persistent microscopic hematuria. This also may cause proteinuria which is usually mild and overall prognosis is excellent.
Sources: en.wikipedia.org
Indium wire is used as a vacuum seal and a thermal conductor in cryogenics and ultra-high-vacuum applications, in such manufacturing applications as gaskets that deform to fill gaps. Owing to its great plasticity and adhesion to metals, Indium sheets are sometimes used for cold-soldering in microwave circuits and waveguide joints, where direct soldering is complicated. Indium is an ingredient in the gallium–indium–tin alloy galinstan, which is liquid at room temperature and replaces mercury in some thermometers. Other alloys of indium with bismuth, cadmium, lead, and tin, which have higher but still low melting points (between 50 and 100 °C), are used in fire sprinkler systems and heat regulators. Indium is one of many substitutes for mercury in alkaline batteries to prevent the zinc from corroding and releasing hydrogen gas. Indium is added to some dental amalgam alloys to decrease the surface tension of the mercury and allow for less mercury and easier amalgamation. Indium's high neutron-capture cross-section for thermal neutrons makes it suitable for use in control rods for nuclear reactors, typically in an alloy of 80% silver, 15% indium, and 5% cadmium. In nuclear engineering, the (n,n') reactions of 113In and 115In are used to determine magnitudes of neutron fluxes.
== Nutrition == Dried chia seeds contain 6% water, 42% carbohydrates (including a high content of dietary fiber), 16% protein, and 31% fat (table). In a reference amount of 100 grams (3.5 oz), chia seeds supply 486 calories and are a rich source (20% or more of the Daily Value, DV) of the B vitamins, thiamin and niacin (52% and 55% DV, respectively). They are also a moderate source of riboflavin (13% DV) and folate (12% DV). The seeds contain dense amounts of several dietary minerals, including calcium, iron, magnesium, manganese, phosphorus, and zinc (all more than 20% DV; table). Chia oil contains a high percentage of essential fatty acids (approximately 60%) and a low content of saturated fatty acids. The fats of chia seed oil are mainly unsaturated, with linoleic acid (17–26% of total fat) and α-linolenic acid (50–57%) as the major fatty acids (see table).
==== Far-right politics ==== Many far right and nationalist parties in Europe, including Alternative for Germany, National Rally, Sweden Democrats, Brothers of Italy, and Reform UK were described as repulsed by Trump's threats against the sovereignty of a European country. Italian prime minister Giorgia Meloni called Trump's statements "unacceptable" and said, "friendship requires respect." Nigel Farage called Trump's threats against Greenland a "very hostile act" against Europe. According to a YouGov poll from February 2026, the crisis also led to an increase of people in Western Europe with an unfavourable opinion of the United States.
The complaint further alleged that the injections caused a permanent loss of mobility and function from which she never recovered, describing the use of the drug as a form of "chemical restraint" and outside the standard of care. The case highlights concerns about the off-label use of antipsychotics in elderly dementia patients, a practice for which the drug carries a black box warning from the FDA due to an increased risk of death. Billy Driver, Jr. is a California prisoner who has been involuntarily administered the long-acting injectable antipsychotic Invega Sustenna (paliperidone palmitate) since at least 2019. He has filed multiple federal civil rights lawsuits alleging the forced medication causes severe side effects, including gynecomastia, borderline diabetes, heart palpitations, chest pain, and kidney pain. In one suit, Driver v. Naranjo (filed January 2024), Driver alleged that psychiatrist Dr. Naranjo at the Richard J. Donovan Correctional Facility (RJD) in San Diego had twice threatened to use physical force if Driver continued to refuse the injections. A judge dismissed Driver v. Naranjo in February 2025, noting that Driver's involuntary medication was authorized by active court orders issued through California's Keyhea process. Since 2020, Driver has undergone six Keyhea hearings, at each of which a court found that if unmedicated he would be a danger to others, that he lacked insight into his own need for medication, and that he could not manage his own treatment.
=== Inflating prices fine (2022) === In July 2022, UK antitrust authorities fined Pfizer £63 million for unfairly pricing a drug that aids in controlling epileptic seizures. The Competition and Markets Authority stated that the company and Flynn took advantage of a loophole by de-branding the epilepsy drug Epanutin (phenytoin sodium capsules). This meant the price of the drug was no longer regulated and the companies could raise the price of the drug unchecked. It was stated that over a four-year period, Pfizer had billed Epanutin for around 780% and 1,600% higher than its standard price.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.